Comparison of Prognosis on Esopageal Carcinoma Treated with 3D-CRT and IMRT for Elderly Patients

Wang Yuxiang; Wang Jun; Zhu Shuchai; Tian Dandan; Lv Dongjie; Wang Yi; Qiao Xueying

doi:10.3971/j.issn.1000-8578.2012.08.031

Cancer Research on Prevention and Treatment > 2012 > 39(08): 1008-1013. > DOI: 10.3971/j.issn.1000-8578.2012.08.031

Wang Yuxiang, Wang Jun, Zhu Shuchai, Tian Dandan, Lv Dongjie, Wang Yi, Qiao Xueying. Comparison of Prognosis on Esopageal Carcinoma Treated with 3D-CRT and IMRT for Elderly Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 1008-1013. DOI: 10.3971/j.issn.1000-8578.2012.08.031

Citation:

PDF (856 KB)

Comparison of Prognosis on Esopageal Carcinoma Treated with 3D-CRT and IMRT for Elderly Patients

Department of Radiation Oncology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China

More Information

Received Date: October 19, 2011
Revised Date: February 01, 2012

Graphical Abstract

Abstract

Abstract

Objective To compare the prognosis of esopageal carcinoma treated with 3-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiation therapy (IMRT) for patients older than 65 years;and to analysis the related factors affected the prognosis. Methods From January 2001 to December 2008, 105 cases of elderly patients with esopageal carcinoma were treated with 3D-CRT and 48 cases with IMRT. Local control rates, survival rates and its related prognostic factors were evaluated retrospectively with SSPS11.5 software. Results After the treatment with 3D-CRT or IMRT, there was 71 cases in CR, 78 in PR, and 4 in NR. The total efficiency (CR+PR) was 97.4%. The 1 and 3-year over-all survival rate was 70.6% and 34.2%, respectively; and the 1- and 3-year local control rate was 76.2% and 51.1%, respectively. Compared with the clinical data between 3D-CRT and IMRT, there were more patients with metastasis of lymph node, located in middle and lower-thoracic carcinoma, larger diameter of tumor in CT, higher dose of radiotherapy agents, and more patients was combination of chemotherapy in IMRT group (P<0.05). There were no significant differences in the effects of gender, age, T stage and diet before radiotherapy and lesion length bariesophagogram between the two groups (P>0.05). There were no significant differences in the 1- and 3-year survival rate and free-recurrence rate between 3D-CRT and IMRT groups(P>0.05). For all patients, analyzed by univariate analysis, the related factors affected on the prognosis were the different diet, site of lesion, T stage, metastasis of lymph node, lesion length in barium esophagogram and CT image, chemotherapy and the immediate response (P＜0.05). By Cox multivariate analysis, the independent factors affected on the prognosis were chemotherapy and the largest diameter of lesion in CT scanning image (P＜0.05). Conclusion s3D-CRT and IMRT can be considered as effective and feasible approaches for elderly patients with esophageal cancer. Chemotherapy and the largest diameter of lesion in CT scanning image were independent prognostic factors for those patients.
- Esophageal neoplasms/Elder patients,
- 3D-CRT / IMRT,
- Survival,
- Prognosis

FullText(HTML)

References (19)

References

[1]	Xiao ZF,Zhang Z,Zhang HZ,et al.Assessment of tumor dose distribution in three dimensional conformal radiotherapy treatment planning system for esophageal cancer[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2004,13(4):273-7.[肖泽芬,章众,张宏志,等,用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-7.]
[2]	Wang L,Han CH,Zhu SC,et al.Dosimetry study on conventional and three dimensional conformal radiotherapy for esophageal cancer[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2006,15(3):176-80.[王澜,韩春,祝淑钗,等.食管癌常规照射与三维适形放疗的剂量学研究[J].中华放射肿瘤学杂志,2006,15(3):176-80.]
[3]	Wang SL,Liao Z,Liu H,et al.Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer[J].World J Gastroenterol,2006,12(34):5501-8.
[4]	Wang J,Zhu SC,Han C,et al.Comparison of dose distribufions between conformal and intensity.modulated radiotherapy for the upper esophageal carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2008,17(4):275-9.[王军,祝淑钗,韩春,等.胸上段食管癌三维适形和调强放疗剂量学对比研究[J].中华放射肿瘤学杂志,2008,17(4):275-9.]
[5]	Zhang ZW,Chen ZJ,Li DR,et al.Dosimetric comparison between intensity-modulated radiotherapy and conformal radiotherapy for upper thoracic esophageal carcinoma[J].Ai Zheng,2009,28(11):1127-31.[张武哲,陈志坚,李德锐,等.胸上段食管癌调强放疗与适形放疗计划的剂量学比较[J].癌症,2009,28(11):1127-31.]
[6]	Wang YX,Zhu SC,Li J,et al.Prognostic analysis of three-dimensional conformal radiotherapy (3DCRT) for 209 cases of esopageal carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2010,19(2):101-4.[王玉祥,祝淑钗,李娟,等.209例食管癌三维适形放疗疗效分析[J].中华放射肿瘤学杂志,2010,19(2):101-4.]
[7]	Wang J,Han C,Li XN,et al.Short-term efficacy of intensity-modulated radiotherapy on esophageal carcinoma[J].Ai Zheng,2009,28(11):1138-41.[王军,韩春,李晓宁,等.食管癌调强放射治疗初期疗效分析[J].癌症,2009,28(11):1138-41.]
[8]	Guo YX.Clinical investigation on the efect and complication of accelerated hyper-fractionation for elderly patients with esophageal carcinoma[J].Zhongguo Zhong Liu Lin Chuang,2006,33(7):386-8.[郭跃信.老年食管癌加速超分割放射治疗的临床探讨[J].中国肿瘤临床,2006,33(7):386-8.]
[9]	Li GW,Guo YX.Radiotherapy of esophageal cancer for elder patients more than 80 years[J].Zhonghua Lao Nian Yi Xue Za Zhi,2007,26(3):202-3.[李国文,郭跃信.80岁以上老年人食管癌的放射治疗[J].中华老年医学杂志,2007,26(3):202-3.]
[10]	Kosugi S,Sasamoto R,Kanda T,et al.Retrospective review of surgery and definitive chemoradiotherapy in patients with squamous cell carcinoma of the thoracic esophagus aged 75 years or older[J].Jpn J Clin Oncol,2009,39(6):360-6.
[11]	Kawashima M,Kagami Y,Toita T,et al.Prospective trail of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus[J].Int J Radiat oncol Biol Phys,2006,64(4):1112-1.
[12]	Jiang J,Wang QF,Xiao ZF,et al.Efficacy of three-dimensional conformal radiotherapy for 132 patients with esophageat carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2009,18(1):47-51.[蒋杰,王奇峰,肖泽芬,等.132例食管癌三维适形放疗的疗效分析[J].中华放射肿瘤学杂志,2009,18(1):47-51.]
[13]	Wang YX,Zhu SC,Su JW,et al.Prognostic analysis of three-dimensional conformal radiotherapy for elderly patients with esophageal carcinoma[J].Zhonghua Lao Nian Yi Xue Za Zhi,2010,29(2):131-4.[王玉祥,祝淑钗,苏景伟,等.老年人食管癌三维适形放射治疗疗效分析[J].中华老年医学杂志,2010,29(2):131-4.]
[14]	Wan X,Qiao XY,Wang YD,et al.Aanlysisi of treatment outcome and prognostic factor with three-dimensional conformal radiotherapy for thoracic esophageal squamous cell carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2011,20(3):202-4.[万欣,乔学英,王雅棣,等.131例食管鳞癌三维适形放疗预后因素分析[J].中华放射肿瘤学杂志,2011,20(3):202-4.]
[15]	Chen EC,Liu MZ,Hu YH,et al.A case-contral study on unresectable esophageal carcinoma patients with radiochemotherapy or radiotherapy[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2007,16(5):416-9.[陈尔成,刘盂忠,胡永红,等.同期放化疗与单纯放疗不能手术食管癌的病例对照研究[J].中华放射肿瘤学杂志,2007,16(5):416-9.]
[16]	Nallapareddy S,Wilding GE,Yang G,et al.Chemoradiation is a tolerable therapy for older adults with esophageal cancer[J].Anticancer Res,2005,259(4):3055-60.
[17]	Anderson SE,Minsky BD,Bains M,et al.Combined modality chemoradiation in elderly oesophageal cancer patients[J].Br J Cancer,2007,96(12):1823-7.
[18]	Zhu SC,Li R,Wang YX,et al.Prognostic factors of locally advanced esophageal carcinoma treated by radiotherapy alone[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2005,14(4):253-8.[祝淑钗,李任,王玉祥,等.500例中晚期食管癌单纯放疗的多因素分析[J].中华放射肿瘤学杂志,2005,14(4):253-8.]
[19]	Chinese expert group of clinical stage for non surgery esophageal cancer.Criterion of clinical stage for non surgery esophageal cancer[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2010,19(3):179-80.[中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准[J].中华放射肿瘤学杂志,2010,19(3):179-80.]

[1]	CHENG Jianping, ZHAO Xiaolin, LI Zhen, YANG Mengyuan, CAO Shichang, YU Jiufei. Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 542-546. DOI: 10.3971/j.issn.1000-8578.2020.19.1475
[2]	XU Qi, LIU Bixia, GU Linhui, ZHANG Shuangshuang, ZHOU Weimin, WU Xiaodan, YING Jieer, FENG Jianguo. Effects of Different Doses of Bevacizumab on Irinotecan Distribution in Nude Mice Bearing Human Colon Cancer Cell Xenografts[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 263-266. DOI: 10.3971/j.issn.1000-8578.2016.04.005
[3]	WANG Junbin, WU Qiong, ZOU Weiyan, WANG Zishu, YANG Yan, ZHENG Rongsheng. Therapeutic Effect of Raltitrexed or Fluorouracil plus Irinotecan as Second-line Treatment for Advanced Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1335-1338. DOI: 10.3971/j.issn.1000-8578.2014.12.018
[4]	CUI Yongxia, LUO Zhifen, LU Chuangxin, ZHOU Jianwei, MA Ning, ZHOU Yun. Clinical Observation of Irinotecan Combined with Tegafur or 5-Fluorouracil as Second-Line Chemotherapy for Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 808-810. DOI: 10.3971/j.issn.1000-8578.2014.07.026
[5]	ZHAO Rongrong, WANG Yuanfang, LIU Bo, HAN Shumei, NIU Zuoxing. Clinical Study of Irinotecan Plus Cisplatin for Patients with Carcinoma of Unknown Primary Site[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 984-987. DOI: 10.3971/j.issn.1000-8578.2013.10.017
[6]	Zhang Huiqing, He Bo, Lu San, Wan Yiye. Second-line Chemotherapy with Irinotecan Plus Cisplatin for Patients with Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(11): 1373-1375. DOI: 10.3971/j.issn.1000-8578.2012.11.023
[7]	LI Rong, LIU Xiu-feng, HE Ze-ming, HUA Hai-qing, WANG Lin, CHEN Ying-xia. Preliminary Clinical Observation on Irinotecan Combined with Continuous Infusion of Tegafur in Treating Patients with Advanced Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020
[8]	LI Min, FANG Ming-zhi, QIAN Yin, HUANG Xin, ZHU Xiang. Cetuximab plus Irinotecan in Treatment of Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(08): 938-941. DOI: 10.3971/j.issn.1000-8578.2010.08.021
[9]	XU Hua, LIU An-wen, XIE Chun-ying, WU Jian-bing. Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemotherapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019
[10]	HUANG Yong, QIN Shu-kui, QIAN Jun, SHAO Zhi-jian, L IU Xiu-Feng, L IAO Shi-bin, GONG Xin-lei. Clinical Study of Weekly Irinotecan in Patients with Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199

Cited By

Get Citation

PDF

XML

Article views (3083) PDF downloads (614)

Turn off MathJax

Article Contents

Abstract

References

Comparison of Prognosis on Esopageal Carcinoma Treated with 3D-CRT and IMRT for Elderly Patients

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Comparison of Prognosis on Esopageal Carcinoma Treated with 3D-CRT and IMRT for Elderly Patients

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content